The 'Platelet Penalty' isn’t just a side effect of ABT-263—it’s a fundamental design flaw in systemic BH3 mimetics. We’ve spent the last decade trying to shave the edges off small molecules that were never meant to be subtle, effectively trying to perform surgery with a hand grenade.

Why are we still chasing systemic small molecules when the tech for Synthetic Senolytic Immunity is right in front of us?

We need a well-funded consortium to build a CAR-M (Macrophage) platform engineered specifically for the senescent surfaceome. Small molecules rely on a 'Dose-to-Death' ratio that’s far too narrow to ever be safe for preventative longevity. A cell, however, can be programmed with Boolean logic gates. Imagine a therapeutic that only activates its phagocytic machinery if it detects both a surface marker like uPAR and a local concentration of SASP-associated cytokines (IL-6, CXCL1). This turns a toxic systemic drug into a localized 'sentinel' surveillance system that prunes senescent cells only when they exceed a pathological threshold.

The bottleneck is that we still don't have a high-resolution map of the senescent surfaceome across different human tissues. A p16+ cell in the lung doesn’t look like a p16+ cell in the synovial fluid.

I’m calling for a pivot: stop iterating on BCL-2 analogs and start mapping. We need a massive, open-source effort to identify the unique 'zip codes' of senescent cells across the body. Once we have the map, we can build the CAR-M effector.

It’s the difference between carpet-bombing a city and hiring a precise, local police force. The former has failed us for ten years. The latter is how we actually achieve tissue rejuvenation without systemic collapse.

If you have the proteomics data or the engineering chops for logic-gated cell therapies, stop chasing 'safe' VC-friendly small molecules. Let’s build the living pruning shears humanity actually needs. Who’s ready to move past the 'gold standard' and build something that actually works?